GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Debt-to-Equity

BioVie (BioVie) Debt-to-Equity : 1.37 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Debt-to-Equity?

BioVie's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.24 Mil. BioVie's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. BioVie's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7.49 Mil. BioVie's debt to equity for the quarter that ended in Dec. 2023 was 1.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioVie's Debt-to-Equity or its related term are showing as below:

BIVI' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2   Med: 0.52   Max: 7.44
Current: 1.37

During the past 11 years, the highest Debt-to-Equity Ratio of BioVie was 7.44. The lowest was -0.20. And the median was 0.52.

BIVI's Debt-to-Equity is ranked worse than
91.17% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs BIVI: 1.37

BioVie Debt-to-Equity Historical Data

The historical data trend for BioVie's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Debt-to-Equity Chart

BioVie Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.04 - 3.34 0.94

BioVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.64 0.94 1.64 1.37

Competitive Comparison of BioVie's Debt-to-Equity

For the Biotechnology subindustry, BioVie's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioVie's Debt-to-Equity falls into.



BioVie Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioVie's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

BioVie's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVie  (NAS:BIVI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


BioVie Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioVie's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie (BioVie) Business Description

Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486

BioVie (BioVie) Headlines

From GuruFocus

BioVie Issues Letter to Shareholders

By Marketwired 07-18-2023